HK1060569A1 - Inhalative solution formulation containing a tiotropium salt - Google Patents

Inhalative solution formulation containing a tiotropium salt

Info

Publication number
HK1060569A1
HK1060569A1 HK04103587A HK04103587A HK1060569A1 HK 1060569 A1 HK1060569 A1 HK 1060569A1 HK 04103587 A HK04103587 A HK 04103587A HK 04103587 A HK04103587 A HK 04103587A HK 1060569 A1 HK1060569 A1 HK 1060569A1
Authority
HK
Hong Kong
Prior art keywords
formulation containing
solution formulation
tiotropium salt
inhalative solution
inhalative
Prior art date
Application number
HK04103587A
Other languages
English (en)
Inventor
Karin Drechsel
Barbara Niklaus-Humke
Christel Schmelzer
Petra Barth
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7661727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1060569(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of HK1060569A1 publication Critical patent/HK1060569A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
HK04103587A 2000-10-31 2004-05-20 Inhalative solution formulation containing a tiotropium salt HK1060569A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10054042 2000-10-31
PCT/EP2001/012296 WO2002036591A2 (de) 2000-10-31 2001-10-24 Inhalative lösungsformulierung mit einem tiotropiumsalz

Publications (1)

Publication Number Publication Date
HK1060569A1 true HK1060569A1 (en) 2004-08-13

Family

ID=7661727

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04103587A HK1060569A1 (en) 2000-10-31 2004-05-20 Inhalative solution formulation containing a tiotropium salt

Country Status (33)

Country Link
EP (1) EP1335729A2 (de)
JP (1) JP4559703B2 (de)
KR (1) KR100983208B1 (de)
CN (1) CN1237970C (de)
AR (1) AR038765A1 (de)
AU (2) AU2002221741B2 (de)
BG (1) BG66425B1 (de)
BR (1) BR0115016A (de)
CA (1) CA2427583C (de)
CZ (1) CZ305033B6 (de)
DE (1) DE10152369A1 (de)
EA (1) EA009068B1 (de)
EC (1) ECSP034570A (de)
EE (1) EE05343B1 (de)
HK (1) HK1060569A1 (de)
HR (1) HRP20030337A2 (de)
HU (1) HUP0301377A3 (de)
IL (2) IL155676A0 (de)
ME (1) ME00242B (de)
MX (1) MXPA03003750A (de)
MY (1) MY132777A (de)
NO (1) NO332524B1 (de)
NZ (1) NZ526024A (de)
PE (1) PE20020518A1 (de)
PL (1) PL361001A1 (de)
SA (1) SA01220503B1 (de)
SK (1) SK288031B6 (de)
TW (1) TWI296934B (de)
UA (1) UA76435C2 (de)
UY (1) UY26991A1 (de)
WO (1) WO2002036591A2 (de)
YU (1) YU33103A (de)
ZA (1) ZA200303045B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE444368T1 (de) 2000-04-28 2009-10-15 Kosan Biosciences Inc Kristallines epothilon d
US20030235538A1 (en) 2002-04-09 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for the administration of an anticholinergic by inhalation
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
JP2007527409A (ja) * 2003-10-09 2007-09-27 インバーセオン、インコーポレイテッド β−アドレナリンインバースアゴニストを用いて気道疾患を治療する方法
SE0303269L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Medicinsk produkt
CA2595791C (en) * 2005-03-16 2013-10-08 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
EP2034990A4 (de) * 2006-05-26 2013-03-06 Dey L P Zerstäubbare zusammensetzungen von quaternären ammonium-muskarin-rezeptor-antagonisten
CN100446770C (zh) * 2007-01-10 2008-12-31 上海现代药物制剂工程研究中心有限公司 丙酸培氯米松水雾剂
TR200907237A2 (tr) * 2009-09-23 2011-04-21 Bi̇lgi̇ç Mahmut Tiotropyum kuru toz kombinasyonu
CN116173025A (zh) * 2018-07-26 2023-05-30 四川海思科制药有限公司 一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用
CN116196298A (zh) * 2018-07-26 2023-06-02 四川海思科制药有限公司 一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
DE4203306A1 (de) * 1992-02-06 1993-08-12 Ig Spruehtechnik Gmbh Asthma oder pulmonal-aerosolzubereitungen mit lecithin
AU721566B2 (en) * 1995-06-27 2000-07-06 Boehringer Ingelheim Kg New stable pharmaceutical preparation for producing propellant-free aerosols
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
AU3153797A (en) * 1996-06-04 1998-01-05 Procter & Gamble Company, The A nasal spray containing an intranasal steroid and an antihistamine
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
JPH10298107A (ja) * 1997-04-25 1998-11-10 Taisho Pharmaceut Co Ltd 医薬組成物
ES2193726T3 (es) * 1998-08-04 2003-11-01 Jago Res Ag Formulaciones de aerosol medicinales.
DE19847968A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen

Also Published As

Publication number Publication date
UY26991A1 (es) 2002-06-20
SK288031B6 (sk) 2012-12-03
WO2002036591A2 (de) 2002-05-10
AU2174102A (en) 2002-05-15
ZA200303045B (en) 2004-04-22
NO20031914L (no) 2003-06-23
HUP0301377A2 (hu) 2003-10-28
WO2002036591A3 (de) 2002-07-25
IL155676A0 (en) 2003-11-23
HUP0301377A3 (en) 2005-12-28
AR038765A1 (es) 2005-01-26
HRP20030337A2 (en) 2005-04-30
UA76435C2 (en) 2006-08-15
ME00242B (de) 2011-05-10
EA009068B1 (ru) 2007-10-26
MEP40708A (en) 2011-02-10
EE200300202A (et) 2003-10-15
KR100983208B1 (ko) 2010-09-20
KR20040010552A (ko) 2004-01-31
BG66425B1 (bg) 2014-04-30
EA200300483A1 (ru) 2003-12-25
NO332524B1 (no) 2012-10-08
TWI296934B (en) 2008-05-21
CZ20031487A3 (cs) 2003-09-17
NZ526024A (en) 2005-10-28
DE10152369A1 (de) 2002-05-08
SA01220503B1 (ar) 2007-03-10
YU33103A (sh) 2006-05-25
EE05343B1 (et) 2010-10-15
IL155676A (en) 2012-05-31
CA2427583C (en) 2008-02-12
PE20020518A1 (es) 2002-07-12
MY132777A (en) 2007-10-31
CN1473044A (zh) 2004-02-04
ECSP034570A (es) 2003-06-25
BG107726A (bg) 2004-11-30
BR0115016A (pt) 2005-05-03
MXPA03003750A (es) 2004-10-15
JP4559703B2 (ja) 2010-10-13
PL361001A1 (en) 2004-09-20
CN1237970C (zh) 2006-01-25
SK5262003A3 (en) 2003-10-07
JP2004523482A (ja) 2004-08-05
NO20031914D0 (no) 2003-04-29
CZ305033B6 (cs) 2015-04-08
CA2427583A1 (en) 2002-05-10
AU2002221741B2 (en) 2007-04-05
EP1335729A2 (de) 2003-08-20

Similar Documents

Publication Publication Date Title
IL147553A0 (en) Moxifloxacin formulation containing common salt
EG24139A (en) New inhalable powder containing tiotropium
EG24478A (en) New inhalable powder containing tiotropium
EG24669A (en) Antivral azaindole derivatives
HK1055963A1 (en) Valsartan salts
PL364223A1 (en) Pharmaceutical salts
HK1078793A1 (en) Aerosol formulation for inhalation comprising a tiotropium salt
PL358020A1 (en) Novel use for complex fluorides
IL155676A0 (en) Inhalative solution formulation containing a tiotropium salt
AU2002221741A1 (en) Inhalative solution formulation containing a tiotropium salt
AU2173802A (en) Inhalative solution formulation containing a tiotropium salt
AU2002221738A1 (en) Inhalative solution formulation containing a tiotropium salt
GB0011807D0 (en) Formulation for inhalation
HUP0300808A3 (en) Fungicidal formulation containing triazolopyridine derivative
AP2003002783A0 (en) Medicament containing activted antihtrombin iii
EP1406592A4 (de) Medizinische salz/ionen-paar-aerosolformulierung
GB0013400D0 (en) A formulation
GB0019132D0 (en) A solution monitor
GB0015079D0 (en) Solution for pharmaceutical use
TW459479U (en) Agent dispenser for aquarium

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20211023